A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 954 participants.

Also called NCT07595549

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 954 participants (planned count) (from the registry)
Sponsor
  • Pfizer Registry lists this organization as the lead sponsor
Registry
  • NCT NCT07595549
  • EU CT 2026-525318-75-00
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Brazil, Canada, France, Germany, Italy, Japan, Mexico, Poland, South Korea, Spain (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07595549. Randomized; double masking; primary purpose treatment. Start 2026-06-10 (actual); primary completion 2028-05-04 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity
Condition
Obesity
Condition
Overweight and/or Obesity
Condition
Overweight
Intervention (Drug)
PF-08653944
Intervention (Other)
Placebo
Lead sponsor
Pfizer (class: industry)

Record details

Record id
cardio:ct-nct07595549
Content hash
75dbbfc48b5941551135acccd91f8e080f79b5fecea52e71831f0ee99d269b87